Last reviewed · How we verify
Asthma — Treatment Landscape & Competitive Intelligence
Respiratory
10 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Dupixent | DUPILUMAB | Regeneron | Interleukin-4 Receptor alpha Antagonist [EPC] | Interleukin-4 receptor subunit alpha | 2017-01-01 | |
| Nucala | MEPOLIZUMAB | GSK | Interleukin-5 Antagonist [EPC] | Interleukin-5 | 2015-01-01 | |
| Incruse Ellipta | UMECLIDINIUM | Glaxo Grp England | Anticholinergic | Muscarinic acetylcholine receptor M4 | 2013-01-01 | |
| Breo Ellipta | VILANTEROL | Glaxo Grp Ltd | beta2-Adrenergic Agonist | Beta-2 adrenergic receptor | 2013-01-01 | |
| Arcapta Neohaler | INDACATEROL | Novartis | beta2-Adrenergic Agonist | Beta-2 adrenergic receptor | 2011-01-01 | |
| Arnuity Ellipta | FLUTICASONE FUROATE | Haleon Us Holdings | Corticosteroid | Glucocorticoid receptor | 2007-01-01 | |
| Omnaris | Alvesco | Takeda Gmbh | ciclesonide | Glucocorticoid receptor | 2006-01-01 | |
| Omnaris | CICLESONIDE | Covis | ciclesonide | Glucocorticoid receptor | 2006-01-01 | |
| Spiriva | TIOTROPIUM BROMIDE | Boehringer Ingelheim | Anticholinergic | Muscarinic acetylcholine receptor M3 | 2004-01-01 | |
| Accolate | ZAFIRLUKAST | Strides Pharma Intl | Leukotriene Receptor Antagonist [EPC] | Cysteinyl leukotriene receptor 1 | 1996-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 14 drugs in Asthma
- Pfizer · 4 drugs in Asthma
- Glaxo Grp England · 2 drugs in Asthma
- Generic (originally Schering) · 2 drugs in Asthma
- Fundacio Privada Mon Clinic Barcelona · 1 drug in Asthma
- GSK · 1 drug in Asthma
- AstraZeneca K.K. · 1 drug in Asthma
- Covis · 1 drug in Asthma
- Generic (originally Merck/Upjohn) · 1 drug in Asthma
- Generic (originally Upjohn/Pfizer) · 1 drug in Asthma
- Generic (originally Merck) · 1 drug in Asthma
- Boehringer Ingelheim · 1 drug in Asthma
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Asthma:
Cite this brief
Drug Landscape (2026). Asthma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/asthma. Accessed 2026-05-15.
Related
- Asthma full disease profile — treatment pathway, diagnostics, guidelines
- Respiratory area landing
- Browse all CI briefs
- Build a custom feed